Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 2/20 | 0.46 |
| ▸ | FASN | P49327 | 1/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13339140 | 0.80 | CA12 (0.56) | CA12CA2CA9CA1CA6 | |
| SCHEMBL2486233 | 0.80 | CA12 (0.56) | CA12CA2CA9CA1CA6 | |
| SCHEMBL2486236 | 0.80 | CA12 (0.56) | CA12CA2CA9CA1CA6 | |
| SCHEMBL28993746 | 0.78 | CA12 (0.60) | CA12CA2CA9CA1CA6 | |
| SCHEMBL23268280 | 0.78 | PRSS1 (0.54) | CA12CA2CA9CA1LMNA | |
| SCHEMBL7359286 | 0.76 | PARP1 (0.61) | CA12CA2CA9CA1CA6 | |
| SCHEMBL29720106 | 0.76 | CA12 (0.64) | CA12CA2CA9CA1CA6 | |
| SCHEMBL206107 | 0.76 | CA12 (0.52) | CA12CA2CA9CA1CA6 | |
| SCHEMBL42942 | 0.76 | CA12 (0.64) | CA12CA2CA9CA1CA6 | |
| SCHEMBL30113067 | 0.76 | CA12 (0.52) | CA12CA2CA9CA1CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | DR. REDDY'S LABORATORIES, INC. | 2008-10-16 | — | — | US | claimed |
| EP-2582799-B1 | BIOCATALYSTS AND METHODS FOR THE SYNTHESIS OF (S)-3-(1-AMINOETHYL)-PHENOL | CODEXIS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| WO-2014060371-A1 | INHIBITORS OF SYK | F. HOFFMANN-LA ROCHE AG (CH) | 2014-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255383-A1 | PREPARATION OF RIVASTIGMINE AND ITS SALTS | ACHE, EHMT1, BCHE | CA12 762/4885CA2 280/4885CA9 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.